Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 69

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 69
---
 to build the company and execute on our strategy. These achievements include the following:

| • |     | In 2024, Ms. Jones led our finance and investor relations functions and had several notable achievements including delivery of strong financial results for 2024 through a disciplined approach to spending, finalizing 2025 budget plans, and most notably securing additional financial security for the organization through the sale of the vorasidenib royalty rights to Royalty Pharma for $905.0 million. |

| • |     | In 2024, Dr. Gheuens led the functions of our research, clinical, and regulatory teams responsible for the significant progress in advancing our earlier stage programs with tebapivat in MDS and SCD as well as executing on our later stage programs with the phase 3 data read-outs and submission of regulatory filings in four regions for thalassemia and furthering the progress in our RISE UP trial for SCD. |

| • |     | In 2024, Mr. Burns led our legal, compliance and intellectual property functions, providing general legal and contract support for the organization as well as playing a key role in the execution of the sale of our vorasidenib royalty rights that increased our financial security to support our growth plans in the coming years. |

50

| • |     | In 2024, Ms. Milanova led our commercial function with a focus on continued growth of sales of PYRUKYND® for treatment of hemolytic anemia in adults with PK deficiency, preparing for potential launch of PYRUKYND® in thalassemia in 2025, and defining our strategy for global commercialization. The continued sales growth of our commercialized PYRUKYND® product earned revenue of $36.5 million for the year ended December 31, 2024 compared to $26.8 million for the prior year. |

Based on company and individual performance, our board of directors approved, upon the recommendation of the compensation & people committee, the 2024 cash incentive payment for Mr. Goff, and the compensation & people committee approved the 2024 cash incentive payments for our other NEOs, as follows:

|                            |     | Target     
 Award as % 
 of Base    
 Salary     |    |   |     | Target    
 Cash      
 Incentive 
 Payment   
 ($)       |         |     | 2024 Actual 
 Cash        
 Incentive   
 Payment ($) |         |     | 202